EE04684B1 - Moraxella catarrhalis v„lismembraani proteiin-106polpeptiid, geenij„rjestus ja selle kasutamine - Google Patents

Moraxella catarrhalis v„lismembraani proteiin-106polpeptiid, geenij„rjestus ja selle kasutamine

Info

Publication number
EE04684B1
EE04684B1 EE9800373A EE9800373A EE04684B1 EE 04684 B1 EE04684 B1 EE 04684B1 EE 9800373 A EE9800373 A EE 9800373A EE 9800373 A EE9800373 A EE 9800373A EE 04684 B1 EE04684 B1 EE 04684B1
Authority
EE
Estonia
Prior art keywords
106pol
peptide
gene sequence
membrane protein
outer membrane
Prior art date
Application number
EE9800373A
Other languages
English (en)
Estonian (et)
Other versions
EE9800373A (et
Inventor
Tucker Kenneth
Plosila Laura
Original Assignee
Antex Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biologics, Inc. filed Critical Antex Biologics, Inc.
Publication of EE9800373A publication Critical patent/EE9800373A/xx
Publication of EE04684B1 publication Critical patent/EE04684B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EE9800373A 1996-05-03 1997-04-28 Moraxella catarrhalis v„lismembraani proteiin-106polpeptiid, geenij„rjestus ja selle kasutamine EE04684B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
PCT/US1997/007679 WO1997041731A1 (en) 1996-05-03 1997-04-28 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof

Publications (2)

Publication Number Publication Date
EE9800373A EE9800373A (et) 1999-04-15
EE04684B1 true EE04684B1 (et) 2006-08-15

Family

ID=24577687

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800373A EE04684B1 (et) 1996-05-03 1997-04-28 Moraxella catarrhalis v„lismembraani proteiin-106polpeptiid, geenij„rjestus ja selle kasutamine

Country Status (25)

Country Link
US (6) US7341727B1 (show.php)
EP (1) EP0900025B1 (show.php)
JP (2) JP4401437B2 (show.php)
CN (2) CN100415871C (show.php)
AR (1) AR006999A1 (show.php)
AT (1) ATE244016T1 (show.php)
AU (1) AU723528B2 (show.php)
BG (1) BG64832B1 (show.php)
BR (1) BR9711090A (show.php)
CA (1) CA2253636C (show.php)
CZ (1) CZ298034B6 (show.php)
DE (1) DE69723254T2 (show.php)
EA (1) EA002743B1 (show.php)
EE (1) EE04684B1 (show.php)
ES (1) ES2202624T3 (show.php)
GE (1) GEP20022695B (show.php)
HU (1) HU223004B1 (show.php)
NO (2) NO324816B1 (show.php)
NZ (1) NZ332896A (show.php)
PL (3) PL189374B1 (show.php)
SK (1) SK284812B6 (show.php)
TW (1) TW541314B (show.php)
UA (1) UA68332C2 (show.php)
WO (1) WO1997041731A1 (show.php)
ZA (1) ZA973809B (show.php)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) * 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
AU4260099A (en) * 1998-05-12 1999-11-29 Smithkline Beecham Biologicals (Sa) Compounds from moraxella catarrhalis
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
CA2374364A1 (en) * 1999-05-24 2000-11-30 Smithkline Beecham Biologicals S.A. Polypeptides and polynucleotides from moraxella catarrhalis
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
DE60035788T2 (de) * 1999-09-14 2008-04-30 Glaxosmithkline Biologicals S.A. Polypeptide aus moraxella (branhamella) catarrhalis
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) * 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
ES2408251T3 (es) 2002-08-02 2013-06-19 Glaxosmithkline Biologicals S.A. Composiciones de vacuna contra Neisseria que comprenden una combinación de antígenos
TWI511739B (zh) 2005-04-08 2015-12-11 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX354843B (es) 2005-12-22 2018-03-22 Glaxosmithkline Biologicals Sa Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
UA92782C2 (ru) 2006-01-17 2010-12-10 Арне Форсгрен Новый поверхностный белок haemophilus influenzae (белок е; ре)
US20100092471A1 (en) * 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
CN101842097B (zh) 2007-07-12 2013-06-19 口腔健康澳洲私人有限公司 用于生物膜治疗的药物组合物
NZ605037A (en) * 2007-07-12 2014-05-30 Oral Health Australia Pty Ltd Immunology treatment for biofilms
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines
TWI473626B (zh) 2008-08-29 2015-02-21 Oral Health Australia Pty Ltd 牙齦紫單胞菌（ｐ.ｇｉｎｇｉｖａｌｉｓ）感染之預防、治療及診斷技術
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
US10022696B2 (en) 2009-11-23 2018-07-17 Cyvek, Inc. Microfluidic assay systems employing micro-particles and methods of manufacture
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
WO2013134745A1 (en) 2012-03-08 2013-09-12 Cyvek, Inc Portable microfluidic assay devices and methods of manufacture and use
CA2781556C (en) 2009-11-23 2015-05-19 Cyvek, Inc. Method and apparatus for performing assays
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN102869378A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
EP3165540A1 (en) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
US8501197B2 (en) 2010-04-30 2013-08-06 The Research Foundation for The State of New York Compositions and methods for stimulating immune response against Moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2689253B1 (en) 2011-03-22 2021-03-10 Cyvek, Inc. Microfluidic devices and methods of manufacture
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
CN116059351A (zh) 2016-04-18 2023-05-05 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IE87439B1 (en) 2017-05-30 2023-10-11 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
BR112020021271A2 (pt) 2018-04-17 2021-01-26 Celldex Therapeutics, Inc. construtos bispecíficos e anticorpos anti- cd27 e anti-pd-l1
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
KR20240006541A (ko) 2021-04-09 2024-01-15 셀덱스 쎄라퓨틱스, 인크. Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) * 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) * 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
CN1222618C (zh) 2005-10-12
SK284812B6 (sk) 2005-12-01
JP2008161194A (ja) 2008-07-17
DE69723254T2 (de) 2004-04-22
HK1021299A1 (en) 2000-06-09
US7128910B2 (en) 2006-10-31
AR006999A1 (es) 1999-10-13
HUP9902695A2 (hu) 1999-12-28
EP0900025A4 (en) 2000-01-05
EA199800973A1 (ru) 1999-06-24
US20020177200A1 (en) 2002-11-28
EP0900025B1 (en) 2003-07-02
EE9800373A (et) 1999-04-15
GEP20022695B (en) 2002-05-27
PL330935A1 (en) 1999-06-07
EP0900025A1 (en) 1999-03-10
BG64832B1 (bg) 2006-06-30
UA68332C2 (en) 2004-08-16
US7914795B2 (en) 2011-03-29
NO324816B1 (no) 2007-12-10
BR9711090A (pt) 1999-08-17
HK1095358A1 (zh) 2007-05-04
US20070087019A1 (en) 2007-04-19
AU3118097A (en) 1997-11-26
PL189375B1 (pl) 2005-07-29
CN100415871C (zh) 2008-09-03
NO985113D0 (no) 1998-11-02
ES2202624T3 (es) 2004-04-01
ATE244016T1 (de) 2003-07-15
EA002743B1 (ru) 2002-08-29
CN1800359A (zh) 2006-07-12
US7576179B2 (en) 2009-08-18
JP4401437B2 (ja) 2010-01-20
WO1997041731A1 (en) 1997-11-13
BG102983A (en) 2000-05-31
ZA973809B (en) 1997-12-01
AU723528B2 (en) 2000-08-31
HUP9902695A3 (en) 2001-02-28
CA2253636A1 (en) 1997-11-13
PL189374B1 (pl) 2005-07-29
HU223004B1 (hu) 2004-03-01
NZ332896A (en) 2000-05-26
US20080145916A1 (en) 2008-06-19
SK150998A3 (en) 1999-05-07
PL189995B1 (pl) 2005-10-31
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
CZ298034B6 (cs) 2007-05-30
US6214981B1 (en) 2001-04-10
CN1223549A (zh) 1999-07-21
DE69723254D1 (de) 2003-08-07
CZ352498A3 (cs) 1999-06-16
NO20063711L (no) 1998-12-28
JP2000510696A (ja) 2000-08-22
US7341727B1 (en) 2008-03-11
US20100021492A1 (en) 2010-01-28
CA2253636C (en) 2003-04-22

Similar Documents

Publication Publication Date Title
EE04684B1 (et) Moraxella catarrhalis v„lismembraani proteiin-106polpeptiid, geenij„rjestus ja selle kasutamine
DE69732871D1 (de) Basisches Protein Zusammensetzung, basisches Peptid Zusammensetzung und deren Verwendung
TR199501527A2 (tr) Yeni peptid bilesimleri.
NO975768D0 (no) Tilkoblings-, skille- og koblingslist
ZA9610721B (en) Grapevine leafroll virus proteins and their uses.
NO985680L (no) Peptidderivater
AU4075797A (en) Outer membrane protein b1 of moraxella catarrhalis
NO983849D0 (no) Peptidderivater
EP1117779A4 (en) -i (MORAXELLA CATARRHALIS) PrPTEIN; NUCLEAR SAUCE SEQUENCE AND APPLICATIONS
NO963487D0 (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
AU5137698A (en) Novel dna, novel protein, and novel antibody
ID19257A (id) Protein-protein anti-obesitas
FI972965A0 (fi) Uusia peptidejä, niiden valmistus ja käyttö
EE200000356A (et) DNA molekul, mis kodeerib mutantset prepro-neuropeptiidi Y, mutantne signaalpeptiid ja nende kasutamine
EE9900092A (et) PTX-tundlikud G-valgud, nende valmistamine ja kasutamine
DE59700382D1 (de) Indiumhaltiger, oxidkeramischer Thermistor
AU6844596A (en) Nucleotide sequence encoding the cd33-like protein
HK1016424A (en) Protein-106 polypeptide of the outer membrane of moraxella catarrhalis, gene sequence and uses thereof
EE9900178A (et) Interleukiin-1ß konverteeriva ensüümiga seonduv peptiid, selle kasutamine ja farmatseutiline kompositsioon
FR2747681B1 (fr) Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
HUP0101911A3 (en) Novel sequence class of genes, corresponding proteins and the use of the same
DE69636231D1 (de) Menschliche chemokin-polypeptide.
NO920500L (no) Nukleotidsekvens som koder for et ytre membranprotein franeisseria meningitidis, samt anvendelse derav
HK1003061A (zh) 海马相关蛋白质，其dna序列编码及用途

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110428